Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage

Table 1 Baseline in the two groups

Baseline	Late treatment group (n = 38)	Early treatment group (n = 38)
Sex (Male/Female)	21/17	22/16
Age (mean ± SD, yr)	47.5 ± 12.6 (22-76)	46.9 ± 12.8 (27-74)
Etiology, n (%)
Gallstones	20 (52.6)	16 (42.1)
Alcohol abuse	2 (5.3)	7 (18.7)
Hyperlipidemia	7 (18.4)	9 (23.7)
Idiopathic	9 (23.7)	6 (15.8)
48-h Ranson score (mean ± SD)	4.5 ± 1.7	4.8 ± 1.6
24-h APACHE II score (mean ± SD)	10.8 ± 3.5	10.2 ± 3.1
CT score (mean ± SD)	5.8 ± 2.3	5.9 ± 2.4

APACHE II: Acute Physiology and Chronic Heath Evaluation II; CT: Computed Tomography.

Table 2 Incidence and duration of complications in the two groups (n, %) (mean ± SD)

Complications	Late treatment group (n = 38)		Early treatment group (n = 38)
	Cases (%)	Duration (d)	Cases (%)	Duration (d)
ARDS	18 (47.4)	12.7 ± 21.0	21 (55.3)	2.7 ± 3.3b
Renal failure	9 (23.7)	5.3 ± 7.3	7 (18.4)	1.3 ± 0.5b
Acute hepatitis	19 (50.0)	7.0 ± 7.1	17 (44.7)	3.2 ± 2.3b
Shock	6 (15.8)	4.8 ± 3.1	9 (23.7)	1.7 ± 0.4a
Encephalopathy	4 (10.5)	9.5 ± 11.0	4 (10.5)	2.3 ± 1.9b
Enteroparalysis	27 (71.1)	3.5 ± 2.2	29 (76.3)	2.2 ± 1.4b

^aP < 0.05,

^bP < 0.01 vs late treatment group; ARDS: acute respiratory distress syndrome.

Table 3 Fifteen-day APACHE II score, hospital stay (d), infection, operation and mortality in the two groups

Prognosis	Late treatment group (n = 38)	Early treatment group (n = 38)
15-d APACHE II score (mean ± SD)	8.6 ± 3.6	5.0 ± 2.4b
Hospital stay (d, mean ± SD)	45.2 ± 27.1	28.8 ± 9.4b
Infection, n (%)	10 (26.3)	3 (7.9)a
Operation, n (%)	13 (34.2)	5 (13.2)a
Deaths, n (%)	8 (21.1)	2 (5.3)a

^aP < 0.05,

^bP < 0.01.